{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:34:45Z","timestamp":1777566885296,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11307-022-01767-5","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T17:05:53Z","timestamp":1661274353000},"page":"384-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-1503","authenticated-orcid":false,"given":"Marjorie R.","family":"Levinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilya N.","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan L.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reece C.","family":"Budinich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Marton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gjermund","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Dannals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-0151","authenticated-orcid":false,"given":"Jordi","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"1767_CR1","first-page":"1279","volume":"41","author":"HJ Wester","year":"2000","unstructured":"Wester HJ, Willoch F, Tolle TR et al (2000) 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. J Nucl Med 41:1279\u20131286","journal-title":"J Nucl Med"},{"key":"1767_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.neuroimage.2009.08.033","volume":"49","author":"C Mueller","year":"2010","unstructured":"Mueller C, Klega A, Buchholz HG et al (2010) Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study. Neuroimage 49:731\u2013737","journal-title":"Neuroimage"},{"key":"1767_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1097\/j.pain.0000000000001282","volume":"159","author":"SJ Thompson","year":"2018","unstructured":"Thompson SJ, Pitcher MH, Stone LS et al (2018) Chronic neuropathic pain reduces opioid receptor availability with associated anhedonia in rat. Pain 159:1856\u20131866","journal-title":"Pain"},{"key":"1767_CR4","first-page":"330","volume":"45","author":"K Raynor","year":"1994","unstructured":"Raynor K, Kong H, Chen Y et al (1994) Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45:330\u2013334","journal-title":"Mol Pharmacol"},{"key":"1767_CR5","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1073\/pnas.77.8.4469","volume":"77","author":"KJ Chang","year":"1980","unstructured":"Chang KJ, Hazum E, Cuatrecasas P (1980) Possible role of distinct morphine and enkephalin receptors in mediating actins of benzomorphan drugs (putative kappa and sigma agonists). Proc Natl Acad Sci U S A 77:4469\u20134473","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1767_CR6","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1073\/pnas.78.7.4141","volume":"78","author":"KJ Chang","year":"1981","unstructured":"Chang KJ, Hazum E, Cuatrecasas P (1981) Novel opiate binding sites selective for benzomorphan drugs. Proc Natl Acad Sci U S A 78:4141\u20134145","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1767_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ddr.20161","volume":"67","author":"G Henriksen","year":"2006","unstructured":"Henriksen G, Willoch F, Talbot PS, Wester HJ (2006) Recent development and potential use of mu- and kappa-opioid receptor ligands in positron emission tomography studies. Drug Develop Res 67:890\u2013904","journal-title":"Drug Develop Res"},{"key":"1767_CR8","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1021\/jm500503k","volume":"57","author":"BW Schoultz","year":"2014","unstructured":"Schoultz BW, Hjornevik T, Reed BJ et al (2014) Synthesis and evaluation of three structurally related (1)(8)F-labeled orvinols of different intrinsic activities: 6-O-[(1)(8)F]fluoroethyl-diprenorphine ([(1)(8)F]FDPN), 6-O-[(1)(8)F]fluoroethyl-buprenorphine ([(1)(8)F]FBPN), and 6-O-[(1)(8)F]fluoroethyl-phenethyl-orvinol ([(1)(8)F]FPEO). J Med Chem 57:5464\u20135469","journal-title":"J Med Chem"},{"issue":"Suppl","key":"1767_CR9","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1002\/ana.410150716","volume":"15","author":"JJ Frost","year":"1984","unstructured":"Frost JJ, Dannals RF, Duelfer T et al (1984) In vivo studies of opiate receptors. Ann Neurol 15(Suppl):S85-92","journal-title":"Ann Neurol"},{"key":"1767_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0969-8051(99)00061-X","volume":"26","author":"BR Zeeberg","year":"1999","unstructured":"Zeeberg BR (1999) Pharmacokinetic computer simulations of the relationship between in vivo and in vitro neuroreceptor subtype selectivity of radioligands. Nucl Med Biol 26:803\u2013809","journal-title":"Nucl Med Biol"},{"key":"1767_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/0024-3205(86)90499-6","volume":"38","author":"JJ Frost","year":"1986","unstructured":"Frost JJ, Smith AC, Wagner HN Jr (1986) 3H-diprenorphine is selective for mu opiate receptors in vivo. Life Sci 38:1597\u20131606","journal-title":"Life Sci"},{"key":"1767_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0006-8993(77)90817-4","volume":"134","author":"SF Atweh","year":"1977","unstructured":"Atweh SF, Kuhar MJ (1977) Autoradiographic localization of opiate receptors in rat brain III. The telencephalon Brain Res 134:393\u2013405","journal-title":"The telencephalon Brain Res"},{"key":"1767_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/1570178617999200719153812","volume":"18","author":"J Marton","year":"2021","unstructured":"Marton J, Cumming P, Bauer B, Henriksen G (2021) A new precursor for the radiosynthesis of 6-O-(2-[(18) F]fluoroethyl)-6-O-desmethyl-diprenorphine ([F-18]FE-DPN) by nucleophilic radiofluorination. Lett Org Chem 18:344\u2013352","journal-title":"Lett Org Chem"},{"key":"1767_CR14","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"J Bonaventura","year":"2021","unstructured":"Bonaventura J, Lam S, Carlton M et al (2021) Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry 26:6704\u20136722","journal-title":"Mol Psychiatry"},{"key":"1767_CR15","first-page":"513","volume":"37","author":"M Ichise","year":"1996","unstructured":"Ichise M, Ballinger JR, Golan H et al (1996) Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 37:513\u2013520","journal-title":"J Nucl Med"},{"key":"1767_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0006-8993(97)00988-8","volume":"778","author":"I Kitchen","year":"1997","unstructured":"Kitchen I, Slowe SJ, Matthes HW, Kieffer B (1997) Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res 778:73\u201388","journal-title":"Brain Res"},{"key":"1767_CR17","doi-asserted-by":"crossref","unstructured":"Cumming P, Marton J, Lilius TO, Olberg DE, Rominger A (2019) A survey of molecular imaging of opioid receptors. Molecules 24:4190.","DOI":"10.3390\/molecules24224190"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01767-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01767-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01767-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T18:27:05Z","timestamp":1678472825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01767-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1767"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01767-5","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences. CAZ is listed as a coinventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as a coinventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. CAZ is listed as coinventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. CAZ has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}